News

Vobarilizumab is the firm’s anti-IL-6R Nanobody, which did not achieve the primary endpoint of dose response based on the modified BILAG-based combined lupus assessment (mBICLA) at week 24.

RiVax has previously been granted orphan drug designation from the US Food and Drug Administration (FDA). The European Commission grants orphan designations for medicines that treat a life-threatening

The companies undertake a wide range of operations to make clinical trials more efficient overall, using Hitachi's advanced digital technology such as AI, aiming to shorten the period

The Phase III IMpower150 study has achieved its co-primary endpoint of overall survival (OS) at the interim analysis and demonstrated that combined lung cancer treatment helped people with

The trial assessing the efficacy and safety of vareniclin for smoking cessation in nicotine dependent adolescents between 12 years and 19 years of age did not achieve its

The World Health Organization (WHO) estimates that the development of resistant bacteria could cause 10 million deaths per year by 2050 if no innovative treatment is developed. Deinove has

In the United States, Tasigna is now indicated for the treatment of adult and pediatric patients one year of age or older with newly diagnosed Ph+ CML-CP. Tasigna

The company said that it had consulted with the US Food and Drug Administration (FDA) and took the decision not to pursue the accelerated approval for the lung

Ilumya selectively adheres to the p19 subunit of IL-23 and suppresses its interaction with the IL-23 receptor to inhibit release of pro-inflammatory cytokines and chemokines. It will be